# PSMA4 as a Druggable Target in Hidradenitis Suppurativa: Evidence From Mendelian Randomization and Single‐Cell Transcriptomics

## TL;DR

This study identifies PSMA4 and MAST3 as potential drug targets for hidradenitis suppurativa, a chronic skin disease, using genetic and transcriptomic analyses.

## Contribution

The study combines Mendelian randomization and single-cell RNA sequencing to identify PSMA4 as a novel druggable target in hidradenitis suppurativa.

## Key findings

- PSMA4 is upregulated in hidradenitis suppurativa lesions and is enriched in CD4+ T cells.
- PSMA4 is linked to pro-inflammatory signaling, particularly the TNF pathway.
- MAST3 is downregulated in hidradenitis suppurativa lesions and is a potential therapeutic target.

## Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with limited treatment options and frequent drug resistance. Novel therapeutic targets are urgently needed. We performed a druggable genome‐wide Mendelian randomization (MR) analysis using blood cis‐expression quantitative trait locus (eQTL) and HS genome‐wide association study (GWAS) data. Colocalization, transcriptomic validation, single‐cell RNA sequencing, and cell–cell communication analyses were integrated to explore gene function and cell‐type specificity. We identified eight genes that showed significant associations with HS through MR analysis. Colocalization analysis further prioritized PSMA4 and MAST3 as the most promising druggable targets for HS. Specifically, PSMA4 (single nucleotide polymorphisms [SNPs] = 10; inverse‐variance weighted [IVW] OR = 1.912, 95% CI: 1.492–2.450, p < 0.001; PP.H4 = 0.975) and MAST3 (SNPs = 15; IVW OR = 0.557, 95% CI: 0.453–0.686, p < 0.001; PP.H4 = 0.832) exhibited strong statistical associations. Transcriptomic validation revealed that PSMA4 was upregulated and MAST3 was downregulated in HS lesions. Further single‐cell analysis revealed that PSMA4 was predominantly enriched in CD4+ T cells and involved in pro‐inflammatory signaling, particularly the tumor necrosis factor (TNF) pathway. PSMA4 and MAST3 are potential therapeutic targets for HS. PSMA4 may promote inflammation via CD4+ T cell‐mediated signaling, offering a novel avenue for treatment development.